Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Ozempic“
Suchtreffer
Begriffe & Kennungen
Ozempic · 4.8 · 10 and no patients had anti-semaglutide neutralising antibodies or anti-semaglutide antibodies with endogenous
Eintrag öffnenOzempic · 4.8 · 2-year cardiovascular outcomes and safety trial In cardiovascular high risk population the adverse reaction pr
Eintrag öffnenOzempic · 4.8 · 7 see footnote in Table 1) are based on a pool of the phase 3a trials excluding the cardiovascular outcomes tr
Eintrag öffnenOzempic · 4.8 · 8 MedDRA Very common Common Uncommon Rare Very Rare Not known system organ class Hepatobiliary Cholelithia dis
Eintrag öffnenOzempic · 4.8 · 9 moderate in severity and of short duration. The events led to treatment discontinuation in 3.9% and 5% of pa
Eintrag öffnenOzempic · 4.8 · Acute pancreatitis The frequency of adjudication-confirmed acute pancreatitis reported in phase 3a clinical tr
Eintrag öffnenOzempic · 4.8 · American Diabetes Association (ADA) classified hypoglycaemia occurred in 11.3% (0.3 events/patient year) of pa
Eintrag öffnenOzempic · 4.8 · Decreased appetite
Eintrag öffnenOzempic · 4.8 · Description of selected adverse reactions
Eintrag öffnenOzempic · 4.8 · Diabetic retinopathy complications A 2-year clinical trial investigated 3 297 patients with type 2 diabetes, w
Eintrag öffnenOzempic · 4.8 · Discontinuation due to an adverse event The incidence of discontinuation of treatment due to adverse events wa
Eintrag öffnenOzempic · 4.8 · Gastrointestinal adverse reactions Nausea occurred in 17% and 19.9% of patients when treated with semaglutide
Eintrag öffnenOzempic · 4.8 · Heart rate increase Increased heart rate has been observed with GLP-1 receptor agonists. In the phase 3a trial
Eintrag öffnenOzempic · 4.8 · Hypoglycaemia No episodes of severe hypoglycaemia were observed when semaglutide was used as monotherapy. Seve
Eintrag öffnenOzempic · 4.8 · Immunogenicity Consistent with the potentially immunogenic properties of medicinal products containing protein
Eintrag öffnenOzempic · 4.8 · In 8 phase 3a trials 4 792 patients were exposed to semaglutide up to 1 mg. The most frequently reported adver
Eintrag öffnenOzempic · 4.8 · In a 40-week phase 3b trial in patients receiving semaglutide 1 mg and 2 mg, nausea occurred in similar propor
Eintrag öffnenOzempic · 4.8 · In a 40-week phase 3b trial in patients receiving semaglutide 1 mg and 2 mg, the majority of the hypoglycaemic
Eintrag öffnenOzempic · 4.8 · In concomitant use with an SGLT2 inhibitor in SUSTAIN 9, constipation and gastro-oesophageal reflux disease oc
Eintrag öffnenOzempic · 4.8 · Injection site reactions Injection site reactions (e.g. injection site rash, erythema) have been reported by 0
Eintrag öffnen